Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Nippon Shinyaku
Nippon Shinyaku
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Viltepso
Viltolarsen
2020-08-12
2031
Duchenne muscular dystrophy
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Viltolarsen
duchenne muscular dystrophy
,
muscular dystrophies
Aglatimagene besadenovec
prostatic neoplasms
ILGINATINIB
essential thrombocythemia
,
polycythemia vera
,
primary myelofibrosis
,
thrombocytosis
,
polycythemia
Microcrystalline cellulose
multiple myeloma
,
plasma cell neoplasms
,
plasmacytoma
Potassium magnesium citrate (4:1:2)
multiple myeloma
,
plasma cell neoplasms
,
plasmacytoma
Potassium nitrate
carcinoma
,
ovarian neoplasms
,
serous cystadenocarcinoma
,
fallopian tube neoplasms
,
carcinosarcoma
,
hereditary breast and ovarian cancer syndrome
,
mullerian mixed tumor
,
recurrence
,
leukemia
,
myeloid leukemia acute
,
precursor cell lymphoblastic leukemia-lymphoma
,
myeloid leukemia
,
precursor t-cell lymphoblastic leukemia-lymphoma
,
acute disease
,
lymphoid leukemia
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use